2 completed, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Lipid Disorder: new trials by email Literature Review of Lipid Disorder trials Research Report on Lipid Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| Effects of Olive Oil and Bran Oil on Antioxidant Levels, Glycemic Control, and Lipid Profile in Patient Type 2 DM olive oil, bran oil - Diabetes Mellitus, Type 2, Oxidative Stress | Phase 1 | Completed | Universitas Indonesia | 10 | 2018-07-02 | 2018-10-16 |
| Vascepa to Accelerate Lipoprotein Uptake and Elimination Icosapent Ethyl 1000 MG [Vascepa] - Lipid Disorder, Triglycerides High | Phase 1 | Completed | University of Pennsylvania | 20 | 2016-01-11 | 2021-11-11 |
Lipid Metabolism Disorders (3) · Dyslipidemias (2) · Hypertriglyceridemia (2) · Diabetes Mellitus, Type 2 (1) · Homozygous Familial Hypercholesterolemia (1) · Hypercholesterolemia (1) · Hyperlipoproteinemia Type V (1) · Metabolic Diseases (1)
Nutritional and Metabolic Diseases (3) · Hyperlipidemias (2) · Metabolic Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemias (1) · Lipid Metabolism, Inborn Errors (1) · Metabolism, Inborn Errors (1)
Olive Oil (1) · Rice Bran Oil (1) · eicosapentaenoic acid ethyl ester (1)
CRISPR Therapeutics AG (1) · Universitas Indonesia (1) · University of Pennsylvania (1)
United States (2) · Australia (1) · Indonesia (1) · New Zealand (1) · United Kingdom (1)
Dwirini R Gunarti, DR (1) · John Millar, PhD (1)